NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024 - NuCana ( NASDAQ:NCNA )

6 days ago

BARCELONA, Spain, Sept. 14, 2024 ( GLOBE NEWSWIRE ) -- NuCana plc NCNA presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor ...

Ticker	Sentiment	Impact
NCNA	Neutral	21 %